An observational study in Stroke Patients, Stroke and Stroke; Sequelae, sponsored by The Florey Institute of Neuroscience and Mental Health. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by The Florey Institute of Neuroscience and Mental Health · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Stroke with a site in Australia — 22 open to participants now, 29 under way, 11 of them phase 3. Stroke · Australia.
Among the 122 studies in Stroke with a site in Australia, this one is the 12th largest by planned enrollment of the 13 observational ones that give a count, is one of 8 that started in 2025, is one of 13 observational ones, reaches primary completion later than 9 of the 28 other live ones, and was the 117th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →22 of the 122 studies in Stroke with a site in Australia are open now. Recruiting first, the newest first:
University of Calgary · Sites in Australia, Canada
Ages 18+
Eli Lilly and Company · Sites in Australia, Argentina, Austria and 35 more countries
Ages 50+
Pharmazz, Inc. · Sites in Australia, United States, Germany and 2 more countries
Ages 18–80
Transverse Medical, Inc. · Sites in Australia
Ages 18+
EMVision Medical Devices Ltd · Sites in Australia, United States
Ages 22+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 51 · Phase 4 10
First in 1996; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 150 across 1,971 observational studies indexed under Stroke.
Median enrollment 569 across the 108 interventional studies, 626 across the 13 observational. Of the 87 that completed or were terminated, 34 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 122 have an industry lead sponsor. The 10 most frequent:
The Florey Institute of Neuroscience and Mental Health is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
The Florey Institute of Neuroscience and Mental Health has 2 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
6 of the studies in Stroke with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT06527261University of MelbourneElectronic Capturing of Activities During REhabilitation for Upper Limb After Stroke | 2026-12 |
| NCT06495671University of MelbourneAustralasian Nanoparticle-mediated Magnetically Enhanced Diffusion for Ischemic Stroke | 2026-12-31 |
| NCT07019493The Florey Institute of Neuroscience and Mental HealthYoung Stroke Service Deep Phenotyping: Exploring Recovery in Young Adult Survivors of Stroke | 2026-12-31 |
| NCT06429332Region SkaneInternational Care Bundle Evaluation in Cerebral Hemorrhage Research | 2027-03-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 122 studies in Stroke with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Investigators are running a small, early-phase research study across several hospitals in Melbourne, Australia. The study will involve up to 100 young adults between the ages of 18 and 55 who have had a stroke. The goal is to test how practical it is to carry out a detailed health assessment process-called "deep phenotyping"-with this group.
This process involves collecting a wide range of information and samples from stroke survivors to better understand each participant's condition. The Investigators will look at how well this approach works in practice, including how easy it is to use, whether it's done consistently, and how acceptable it is to participants.
At the same time, the Investigators will also explore how different factors-such as biological markers (biomarkers), age, sex, type of stroke, lifestyle, and environment-might be related to stroke recovery. This pilot study will prepare for larger studies in the future.
Young adult stroke survivors within 3 months of stroke
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Severe, intercurrent or progressive illness likely to EITHER
Other: Observational Cohort
The deep phenotyping observational study observes young adult stroke recovery trajectories and will also explore potential recovery biomarkers via: advanced MRI imaging; samples including blood, saliva, urine and hair stored for future analysis that may include (but is not limited to) proteomics, genomics and cortisol; and, a PET scan sub study involving \~20 participants (additional inclusion criteria) exploring the association of reactive astrogliosis with recovery outcomes using the experimental Positron Emission Tomography 18F-SMBT-1 tracer (AU TGA CTN in place). Associations with personal and environmental factors including: physical activity and sleep quality via device (Actigraph and Somfit) and self-report; exposures such as home and work environments, diet, socioeconomic status, and dental health; quality of life, resilience, and locus of control. Monitor healthcare utilisation, changes in medication and medical condition, participant experience and response to the assessments.
Also known as: Deep phenotyping
Implementability (feasibility, fidelity and acceptability)
Evaluation of the implementability will include assessment of the protocol's: * Feasibility, e.g. * Recruitment rate * Retention * Proportion of participants screened that enrolled * Safety via adverse events * Fidelity, e.g. * Proportion of assessments attended * Proportion of data collected and biobanked or analysed * Acceptability, e.g. o Participant acceptability surveys
Time frame: From enrolment to the six month assessment visit
Fatigue Severity Scale
FSS: A 9-item (or 7-item with the first two items removed) measure of fatigue impairment. Measured at baseline (\<1month post stroke), 3- and 6-months post stroke.
Time frame: 6 months
Visual Analogue Scale to Assess Fatigue (VAS-F)
18-item visual analogue scale of fatigue and energy items.
Time frame: Assessment at <1, 3- and 6-months post stroke
Modified Fatigue Impact Scale (MFIS) is a multidimensional scale that reports physical, psychological and cognitive aspects of fatigue
A multidimensional 21-item measure that evaluates physical, psychological and cognitive aspects of fatigue. Measured at baseline (\<1month post stroke), 3- and 6-months post stroke.
Time frame: 6 months
Cognitive Assessment
Assessment to evaluate cognitive domains such as visuospatial memory, auditory verbal learning, visual attention, task switching, verbal fluency, and verbal short-term and working memory. Assessment \<1-month, 3- and 6-months post stroke.
Time frame: 6 months
modified Rankin Scale (mRS)
Single-item evaluation of global disability. Assessed at \<1-month, 3- and 6-months post stroke
Time frame: 6 months
10 metre walk test (10mWT)
Gait assessment, evaluated \<1-month, 3- and 6-months post stroke
Time frame: 6 months
Visual Analogue Scale of the Impact of Fatigue on Communication Ability
Visual analogue scale (0-10) assessing the impact of fatigue on communication ability. Measured at baseline (\<1month post stroke), 3- and 6-months post stroke.
Time frame: 6 months
Plan to share: Undecided — Sharing of individual patient data will be considered upon reasonable request by qualified researchers with appropriate IRB/HREC approval
No publications or documents are linked to this record.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
Of 838 non-industry observational studies under Stroke, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 92. This study's planned 17 months is below that.
Counting every sponsor, half of 900 studies reached it within 40 months; a quarter within 18 and three quarters within 85.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Florey Institute of Neuroscience and Mental Health